1 – 5 of 5
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Etranacogene dezaparvovec gene therapy for haemophilia B (HOPE-B) : 24-month post-hoc efficacy and safety data from a single-arm, multicentre, phase 3 trial
2024) In The Lancet Haematology(
- Contribution to journal › Article
- 2014
-
Mark
Advancing personalized care in hemophilia A: ten years' experience with an advanced category antihemophilic factor prepared using a plasma/albumin-free method.
(
- Contribution to journal › Scientific review
- 2009
-
Mark
Genetic Factors Associated with Inhibitor Development in Hemophilia A: Initial Results From the Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort
(
- Contribution to journal › Published meeting abstract
- 2008
-
Mark
Surgical evaluation of a recombinant factorVIII prepared using a plasma/albumin-free method: Efficacy and safety of Advate in previously treated patients
(
- Contribution to journal › Article
- 1997
-
Mark
Factor IX inhibitors and anaphylaxis in hemophilia B
(
- Contribution to journal › Article